EDEN.L

Eden Research Plc
Eden Research plc - Ecovelex Approval in Italy
7th November 2024, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3377L
Eden Research plc
07 November 2024
 

As the information in this release pertains to EDEN RESEARCH PLC, this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

07 November 2024

 

Eden Research plc Equity Research & Stock Reports | Research ...

 

Eden Research Plc

("Eden" or "Company")

 

Eden Research Announces Ecovelex™ 2024 Approval in Italy

 

Latest approval extends Ecovelex's approval in Italy, providing farmers with continued access to sustainable seed treatments to repel birds for the 2025 growing season

 

Eden Research plc ("Eden") is pleased to announce that Ecovelex™ 2024 has been granted, according to Reg. EU/1107/2009, approval in Italy for use as a bird repellent seed treatment in corn for the 2025 growing season. Eden is a leader in sustainable biopesticide and biocontrol products and technologies.

 

Developed by Eden, Ecovelex represents a new entrant into the seed treatment market and is a replacement for conventional chemicals that are not approved in the EU and UK. It was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. 

 

Ecovelex works by emitting an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources.

 

The product, developed by Eden at its Oxfordshire facility, is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine® plastic-free microencapsulation system. It is designed to support farmers as they strive to meet consumer and regulatory demands for more sustainable agriculture.

 

In 2023, Eden submitted the regulatory dossier and application to Austria, which will act as the interzonal rapporteur member state on behalf of the EU. Review and authorization is expected to take between 18 and 24 months, with each EU member state then able to ratify the authorization or require additional information before granting local authorizations.

 

Sean Smith, Eden CEO, said, "As a developer of crop protection products which use innovative plant-derived chemistry, Eden is delighted that its partnership with one of the industry's leading companies continues to produce results that benefit farmers, the environment, and ultimately, consumers.

 

I believe that today's news is a strong endorsement of its performance over the past year, helping farmers protect their crops against bird infestation in a sustainable manner. It also provides a clear indication that there is a need amongst the farming community for an alternative, sustainable solution which can act as a direct replacement for conventional seed treatments."

 

 

For further information contact:

 

Eden Research plc

www.edenresearch.com

Sean Smith
Alex Abrey

 

 

01285 359 555



Cavendish Capital Markets Limited (Nominated advisor and broker)


Giles Balleny / George Lawson (Corporate Finance)
Charlie Combe (Broking)

Michael Johnson (Sales)

 

 

 

020 7397 8900



Hawthorn Advisors (Financial PR)


Victoria Ainsworth

 

eden@hawthornadvisors.com

 

 

 

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's seed treatment product, EcovelexÔ was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, U.S. and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com.

 

Follow Eden on LinkedInTwitter and YouTube

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAFSFSMWELSEIF]]>
TwitterFacebookLinkedIn